Rhofade Approval History
Rhofade (oxymetazoline hydrochloride) is a topical alpha1A adrenoceptor agonist vasoconstrictor for the treatment of persistent facial erythema associated with rosacea in adults.
Development History and FDA Approval Process for Rhofade
|Jan 19, 2017||Allergan Announces FDA Approval of Rhofade (oxymetazoline hydrochloride) Cream for Facial Erythema Associated with Rosacea|
|May 24, 2016||Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.